X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NKT3447 is an oral, selective inhibitor of CDK2 which reduces cyclin E expression. It is being evaluated for the treatment of patients with cancers driven by cyclin E amplification or overexpression.
Lead Product(s): NKT3447
Therapeutic Area: Oncology Product Name: NKT3447
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2024
Details:
The collaboration aims to evaluate NKT2152, a small molecule that inhibits hypoxia inducible factor 2α (HIF2α), in combination with standard-of-care Tecentriq (atezolizumab) and Avastin (bevacizumab) in first-line treatment of unresectable/advanced hepatocellular carcinoma.
Lead Product(s): NKT2152,Atezolizumab,Bevacizumab
Therapeutic Area: Oncology Product Name: NKT2152
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 08, 2023
Details:
Under the terms of the agreement, Hansoh will be responsible for all the development costs for NKT2152 in Greater China and will receive the exclusive rights to develop and commercialize NKT2152 in the region.
Lead Product(s): NKT2152
Therapeutic Area: Oncology Product Name: NKT2152
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hansoh Pharma
Deal Size: $218.0 million Upfront Cash: $15.0 million
Deal Type: Collaboration May 03, 2022
Details:
The anti-tumor effect observed in several xenograft models suggests NKT2152, a HIF2α inhibitor, may have broader activity in other solid tumors beyond ccRCC that lack a VHL gene deficiency.
Lead Product(s): NKT2152
Therapeutic Area: Oncology Product Name: NKT2152
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
The collaboration with NiKang, will play an important role in the advancement of both tivozanib and NKT2152 program. Under the terms of the agreement, NiKang will sponsor the trial and AVEO will co-fund the trial. Both companies will provide its respective drugs at no cost.
Lead Product(s): NKT2152,Tivozanib
Therapeutic Area: Oncology Product Name: NKT2152
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: Aveo Oncology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 05, 2022
Details:
Proceeds will be used to advance the company’s lead drug candidates into the clinic, expand the pipeline and fund internal drug discovery programs.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cormorant Asset Management
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing May 26, 2021
Details:
Under the terms of the collaboration, Hansoh Pharma will be responsible for leading development and commercialization of NKT-1992 in Greater China.
Lead Product(s): NKT-1992
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hansoh Pharma
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration April 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
